Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid

Inclusion Criteria: * The volunteer has received pentavalent botulinum toxoid for occupational protection under BB IND 0161, with the previous pentavalent botulinum toxoid dose at least 6 months prior to the planned rBV A/B dose. * The volunteer is between the ages of 18 and 69 years at the time of consent. * The volunteer is healthy and has an acceptable medical history. * The volunteer meets the subject suitability requirements and recommendations for source plasma donors (for Part 2 subjects only). * The volunteer, if female and of childbearing potential, is not pregnant or lactating, and agrees to use an acceptable form of FDA-approved contraception for the duration of the study. * The volunteer has the ability to understand the requirements of the study and provide informed consent. * The volunteer agrees to complete the subject diary on a daily basis for 7 days post-vaccination and to report concomitant medication and adverse events during the study period. * The volunteer provides written authorization for use and disclosure of protected health information. * The volunteer agrees not to donate blood or blood products (outside of study procedures) during the course of the study. * The volunteer has personal health insurance. Exclusion Criteria: * Be pregnant or nursing * The volunteer has a history of laboratory evidence of syphilis, acquired immunodeficiency syndrome, Creutzfeldt-Jakob disease, or infection with human immunodeficiency viruses 1 or 2, human T cell ly…